Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | FDPS | P14324 | 5/20 | 0.41 |
| ▸ | HMGCR | P04035 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1852629 | 0.94 | PPARD (0.43) | PPARDFDPSHMGCRPOLBPTPN1 | |
| SCHEMBL9063345 | 0.85 | PPARD (0.46) | PPARDFDPSHMGCRPOLBTSHR | |
| SCHEMBL28339006 | 0.82 | PPARD (0.41) | PPARDPOLBPTPN1TSHRCYP3A4 | |
| SCHEMBL13334729 | 0.81 | FDPS (0.52) | FDPSHMGCRPOLBTSHRCYP3A4 | |
| SCHEMBL17577640 | 0.80 | FDPS (0.36) | FDPSHMGCRPOLBTSHRTP53 | |
| SCHEMBL2539471 | 0.80 | FDPS (0.36) | FDPSHMGCRPOLBTSHRTP53 | |
| SCHEMBL8602788 | 0.80 | CPB2 (0.39) | FDPSHMGCRPOLBTSHRTP53 | |
| SCHEMBL1846885 | 0.79 | FFAR4 (0.44) | PPARDPTPN1TSHRTDP1 | |
| SCHEMBL2541218 | 0.79 | TSHR (0.39) | FDPSHMGCRPOLBTSHRTP53 | |
| SCHEMBL8811318 | 0.79 | MEN1 (0.40) | FDPSHMGCRPOLBTSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946144-B2 | Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2015-02-03 | — | — | US | disclosed |
| US-8524691-B2 | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2013-09-03 | — | — | US | disclosed |
| EP-1928890-B1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS INC (CA) | 2013-04-03 | — | — | EP | disclosed |
| US-8404664-B2 | Phosphonated Rifamycins and uses thereof for the prevention and treatment of bone and joint infections | TARGANTA THERAPEUTICS, INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-20110263534-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2324041-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | Targanta Therapeutics Corp. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100113333-A1 | PHOSPHONATED GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS, INC. (CA) | 2010-05-06 | — | — | US | disclosed |
| WO-2010019511-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-2097440-A1 | PHOSPHONATED GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | Targanta Therapeutics Inc. (CA) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008077241-A1 | PHOSPHONATED GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS, INC. (CA) | 2008-07-03 | — | — | WO | disclosed |
| EP-1928890-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | Targanta Therapeutics Inc. (CA) | 2008-06-11 | — | — | EP | disclosed |
| EP-1881974-A2 | PHOSPHONATED FLUOROQUINOLONES, ANTIBACTERIAL ANALOGS THEREOF, AND METHODS FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | Targanta Therapeutics Inc. (CA) | 2008-01-30 | — | — | EP | disclosed |
| WO-2007138381-A2 | PHOSPHONATED OXAZOLIDINONES AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS INC. (CA) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007096703-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS INC. (CA) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007017762-A2 | PHOSPHONATED FLUOROQUINOLONES, ANTIBACTERIAL ANALOGS THEREOF, AND METHODS FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017762-A2 | PHOSPHONATED FLUOROQUINOLONES, ANTIBACTERIAL ANALOGS THEREOF, AND METHODS FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| US-5563128-A | ANTICHOLESTEROL AGENT | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-10-08 | — | — | US | disclosed |
| WO-1995028155-A1 | PHOSPHONATE DERIVATIVES OF LIPOPHILIC AMINES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| US-5441946-A | Anticholesterol agents | RHONE-POULENC-RORER PHARMACEUTICALS, INC. (US) | 1995-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113333-A1 | PHOSPHONATED GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | PGLS, BPGM, PAG1 | PPARD 2479/4885FDPS 359/4885HMGCR 997/4885 |
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | BPGM, SOST, PSPH | PPARD 2259/4885FDPS 7/4885HMGCR 157/4885 |
| US-20110263534-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | BPGM, SOST, PSPH | PPARD 2259/4885FDPS 7/4885HMGCR 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.